

Prof. Dr. med. Joachim Wachtlin

Chefarzt Augenheilkunde

Vorstandstätigkeiten, Mitgliedschaften, Ämter

- BVA (Berufsverband der Augenärzte) Beirat des Vorstands
- DOCH (Deutsche Ophthalmologische Chefärzte)
- BDOC (Bund Deutscher Ophthalmochirurgen)
- DOG (Deutsche Ophthalmologische Gesellschaft)
- AAO (American Academy of Ophthalmology)
- Augenverbund Berlin
- QS Kommission IVOM und PDT (KV Berlin), Vorsitzender
- Mitglied der Makulakommission von DOG, BVA und RG
- Mitglied der gemeinsamen Weiterbildungskommission der DOG und des BVA
- Verantwortlicher E-learning IVOK Kurs der DOG (Deutsche Ophthalmologische Gesellschaft)
- Jury Videopreis DOG (Deutsche Ophthalmologische Gesellschaft)
- Gutacher Programmkommission DOG

Ehemalige Tätigkeiten

- BVA (Berufsverband der Augenärzte) Beirat des Vorstands
- langjährige Tätigkeit (14 Jahre) im Vorstand der Berlin Brandenburgischen Augenärztlichen Gesellschaft (BBAG) bis 2025
- langjährige Tätigkeit (9 Jahre) im Vorstand der Retinologischen Gesellschaft Deutschland (RG) Gesellschaft (BBAG) bis 2025
- langjähriges Mitglied der Weiterbildungskommission der Ärztekammer Berlin bis 2025

Lehre

Lehrbefugnis MHB, Medizinische Hochschule Brandenburg

Lehrtätigkeit

- Regelmäßige Lehrtätigkeit an der MHB ab dem SoSe 2018, seit der Umhabilitation im Januar 2018
- Davor regelmäßige Lehrtätigkeit Charité Berlin vor und nach der Habilitation 2007
- Prüfer Staatsexamina
- Prüfer und Gutachter Promotions-/ Habilitationsarbeiten
- Regelmäßige Zertifizierungs- und Ausbildungskurse für Augenärzte bei regionalen, nationalen und internationalen Kongressen

Reviewtätigkeit

Gutachten und Review für wissenschaftliche Zeitschriften u.a.:

- Gutachter DOG Tagung
- Graefe`s Arch Clin Exp Ophthalmol
- Ophthalmic research
- Der Ophthalmologe
- ADIS Drug Evaluation
- Expert Opinion Drug Saf

Klinische Studien

- PI, I, und LKP bei zahlreiche (ca. 30 Multizenterstudien) Phase 3, 3a und 4 in den letzten 15 Jahren im Bereich: Netzhaut, Makula, Glaukom.
- Zusammenschlüsse mit anderen klinischen Wissenschaftlern in Studiengruppen zur Evaluation von intravitrealen Therapiestrategien bei Makulaerkrankungen.

Studium

1986 – 1994	Medizinstudium an der Freien Universität Berlin
1994	Experimentelle Promotion über das Thema refraktive Hornhautchirurgie mit der Note "magna cum laude" im Fachbereich Humanmedizin, Augenklinik, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin (Prof. Hoffmann)

Beruflicher Werdegang

1994 – 1996	Arzt im Praktikum in der Abteilung für Augenheilkunde der Charité, Humboldt Universität Berlin (Prof. Hartmann)
1996	Approbation als Arzt (Ärzttekammer Berlin)
1997 – 2002	Wissenschaftlicher Mitarbeiter und Arzt in der Augenklinik Universitätsklinikum Benjamin Franklin, Freie Universität Berlin (Prof. Foerster)
2001	Facharzt für Augenheilkunde, Landesärztekammer Berlin
2001	Oberarzt an der Augenklinik, Charité -Universitätsmedizin Berlin, Campus Benjamin Franklin unter der Leitung von Prof. Foerster
2002	Wissenschaftlicher Assistent, Augenklinik, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin unter der Leitung von Prof. Foerster
2005	Habilitation und Lehrbefugnis im Fach Augenheilkunde an der Charité-Universitätsmedizin Berlin (Thema: Behandlung choroidaler Neovaskularisationen mittels Photodynamischer Therapie)
Seit 2007	Chefarzt Augenabteilung Sankt Gertrauden-Krankenhaus, Berlin
Januar 2018	Umhabilitation an die Medizinische Hochschule Brandenburg (MHB)
Seit Sommer 2021	Professor für Augenheilkunde an der Medizinischen Hochschule Brandenburg (MHB)

Publikationen

Herausgeber und Autor von verschiedenen Lehrbüchern

- [Methylomes of human CD4 and CD8 memory T lymphocytes reveal tissue-specific epigenetic signatures for maintenance and recall function.](#) Deng X, Du W, Gasparoni G, Salhab A, Nordström K, Li J, Wagner V, Zhang E, Wachtlin J, Bodo J, Reinke S, Lei H, Perka C, Hardt S, Dörner T, Holmer C, Tönnies M, Bauer T, Chang HD, Polansky JK, Walter J, Durek P, Radbruch A, Dong J. *Immun Inflamm.* 2025;1(1):13. doi: 10.1007/s44466-025-00009-x. Epub 2025 Oct 1. PMID: 41262706 **Free PMC article.**
- [Correction: Significant increase of firework induced eye injuries in Germany and The Netherlands- are we doing enough to protect minors and bystanders?](#) Gabel-Pfisterer A, Lang SJ, Boehringer D, Agostini H, de Geus LC, de Faber JT; German firework study group. *Graefes Arch Clin Exp Ophthalmol.* 2025 Nov;263(11):3283-3285. doi: 10.1007/s00417-025-06970-y. PMID: 41099827 **Free PMC article.**
- [dherence to Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: 24-Month Results from the ANDROMEDA Study.](#) Holz FG, Ziemssen F, Bauer-Steinhilber U, Wachtlin J, Schürks M, Lorenz K, Scholz P, Machewitz T, Rech C, Lanzl I, Lommatzsch A, Finger RP; ANDROMEDA Study Group. *Ophthalmol Retina.* 2025 Sep 16:S2468-6530(25)00413-0. doi: 10.1016/j.oret.2025.09.004. Online ahead of print. PMID: 40967488 **Free article.**
- [Significant increase of firework induced eye injuries in Germany and The Netherlands- are we doing enough to protect minors and bystanders?](#) Gabel-Pfisterer A, Lang SJ, Boehringer D, Agostini H, de Geus LC, de Faber JT; German firework study group. *Graefes Arch Clin Exp Ophthalmol.* 2025

Apr;263(4):1157-1165. doi: 10.1007/s00417-024-06677-6. Epub 2024 Dec 4.PMID: 39627464 **Free PMC article.**

- [\[Aflibercept in a real-world setting: the AURIGA study : 24-month results of the German cohort of treatment-naïve patients with macular edema following retinal vein occlusion receiving intravitreal aflibercept\]](#). Wachtlin J, Kaymak H, Hoerauf H, Allmeier H, Machewitz T, Scholz P, Schürks M, Feltgen N.Ophthalmologie. 2024 Aug;121(8):650-657. doi: 10.1007/s00347-024-02051-3. Epub 2024 Jul 8.PMID: 38976039
- [Descemet's membrane endothelial keratoplasty is the predominant keratoplasty procedure in Germany since 2016: a report of the DOG-section cornea and its keratoplasty registry.](#) Flockerzi E, Turner C, Seitz B, Collaborators GSG; GeKeR Study Group.Br J Ophthalmol. 2024 May 21;108(5):646-653. doi: 10.1136/bjo-2022-323162.PMID: 37586835 **Free PMC article.**
- [KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.](#) Wykoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS, Agostini HT, Chang A, Laude A, Wachtlin J, Kovacic L, Wang L, Wang Y, Bouillaud E, Brown DM.Am J Ophthalmol. 2024 Apr;260:70-83. doi: 10.1016/j.ajo.2023.07.012. Epub 2023 Jul 15.PMID: 37460036 **Free article**
- [See clearer: survey on the subjective and objective information levels as well as perception and information transfer using virtual reality headsets in patients with diabetic macular edema receiving anti-VEGF treatment.](#) Enders C, Duncker T, Schürks M, Scholz P, Dörner J, Müller C, Wachtlin J, Lommatzsch A.Graefes Arch Clin Exp Ophthalmol. 2023 Jun;261(6):1563-1570. doi: 10.1007/s00417-022-05942-w. Epub 2022 Dec 23.PMID: 36562802 **Free PMC article.**
- [\[Anti-VEGF therapy in neovascular age-related macular degeneration : Statement of the German Society of Ophthalmology \(DOG\), the German Retina Society \(RG\) and the German Professional Association of Ophthalmologists \(BVA\). Stand 15.10.2022\].](#) Deutsche Ophthalmologische Gesellschaft (DOG); Retinologische Gesellschaft e. V. (RG); Berufsverband der Augenärzte Deutschlands e. V. (BVA).Ophthalmologie. 2023 Feb;120(2):169-177. doi: 10.1007/s00347-022-01773-6. Epub 2022 Dec 13.PMID: 36512119
- [\[Pandemic-related sales ban of fireworks in Germany leads to a significant reduction of firework-related eye injuries\].](#) Gabel-Pfisterer A, Böhringer D, Agostini H; Feuerwerks-Verletzungen-Studiengruppe.Ophthalmologie. 2022 Dec;119(12):1257-1266. doi: 10.1007/s00347-022-01778-1. Epub 2022 Nov 30.PMID: 36449087 **Free PMC article**
- [Main Principles of Vitrectomy Using Intraocular Tamponades – A Basic Course in Surgery.](#) Framme C, Sachs HG, **Wachtlin J**, Bechrakis NE, Hoerauf H, Gabel VP.Klin Monbl Augenheilkd. 2022 Nov;239(11):1337-1353. doi: 10.1055/a-1929-9413. Epub 2022 Nov 21.PMID: 36410334 **Free PMC article.**
- [Retinal Vascular Occlusion after COVID-19 Vaccination: More Coincidence than Causal Relationship? Data from a Retrospective Multicentre Study.](#) Feltgen N, Ach T, Ziemssen F, Quante CS, Gross O, Abdin AD, Aisenbrey S, Bartram MC, Blum M, Brockmann C, Dithmar S, Friedrichs W, Guthoff R, Hattenbach LO, Herrlinger KR, Kaskel-Paul S, Khoramnia R, Klaas JE, Krohne TU, Lommatzsch A, Lueken S, Maier M, Nassri L, Nguyen-Dang TA, Radeck V, Rau S, Roeder J, Sandner D, Schmalenberger L, Schmidtman I, Schubert F, Siegel H, Spitzer MS, Stahl A, Stingl JV, Treumer F, Viestenz A, **Wachtlin J**, Wolf A, Zimmermann J, Schargus M, Schuster AK.J Clin Med. 2022 Aug 30;11(17):5101. doi: 10.3390/jcm11175101.PMID: 36079030 **Free PMC article**
- [\[Avoiding mistakes in anti-VEGF intravitreal injection therapy\].](#) Framme C, Junker B, Feltgen N, Hoerauf H, Striebe NA, **Wachtlin J**, Volkmann I.Ophthalmologie. 2022 Mar;119(3):309-326. doi: 10.1007/s00347-021-01553-8. Epub 2022 Jan 14.PMID: 35029746
- Du W, Lenz D, Köhler R, Zhang E, Cendon C, Li J, Massoud M, **Wachtlin J**, Bodo J, Hauser AE, Radbruch A, Dong J. [Rapid Isolation of Functional ex vivo Human Skin Tissue-Resident Memory T Lymphocytes.](#) Front Immunol. 2021 Mar 22;12:624013. doi: 10.3389/fimmu.2021.624013. eCollection 2021.PMID: 33828548.
- Eter N, Hasanbasic Z, Keramas G, Rech C, Sachs H, Schilling H, **Wachtlin J**, Wiedemann P, Framme C; PERSEUS Study Group. [PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration.](#) Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2213-2223. doi: 10.1007/s00417-021-05073-8. Epub 2021 Feb 6.PMID: 33547967.

- Ziemssen F, Hammer T, Grueb M, Mueller B, Berk H, Gamulescu MA, Voegeler J, **Wachtlin J**, Ocean Study Group. [Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial](#). J Ophthalmol 2020 Oct; 2020:8652370. doi 10.1155/2020/8652370. eCollection 2020.PMID:33083052 (IF 1,47)
- **Wachtlin J**, Eter N, Hasanbasic Z, Keramas G, Rech C, Sachs H, Schilling H, Wiedemann P, Framme C. [Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study](#). Graefes Arch Clin Exp Ophthalmol. 2020 Aug 13. doi: 10.1007/s00417-020-04803-8. (IF 2,39)
- Schargus M, **Wachtlin J**, Aisenbrey S, Blum M, Framme C, Hattenbach LO, Hoerauf H, Kaskel-Paul S, Geerling G. [\[Current situation of allocation of academic medical personnel in ophthalmology departments in Germany\]](#). 2020 Aug 6. doi: 10.1007/s00347-020-01203-5. Online ahead of print. PMID: 32761414 (IF 0,698)
- **Wachtlin J**, Spital G, Schmitz-Valckenberg S, Liakopoulos S, Vögeler J, Müller B, Ziemssen F, Ocean Study Group. [Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany](#). J Ophthalmol. 2020 Jul 16;2020:8024258. doi: 10.1155/2020/8024258. E Collection 2020.PMID: 32724669 (IF 1,44)
- Meyer CH, Szurman P, Haritoglou C, Maier M, Wolf A, Lytvynchuk L, Priglinger S, Hillenkamp J, **Wachtlin J**, Becker M, Mennel S, Koss MJ. [Application of subretinal fluid to close refractory full thickness macular holes: treatment strategies and primary outcome: APOSTEL study](#). Graefes Arch Clin Exp Ophthalmol. 2020 Jun 24. doi: 10.1007/s00417-020-04735-3. Online ahead of print. PMID: 32583283 (IF 2,39)
- Steel DHW, Patton N, Stappler T, Karia N, Hoerauf H, Patel N, **Wachtlin J**, Raber T, Kozma-Wiebe P. [OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study](#). Retina. 2020 Jun 2. doi: 10.1097/IAE.0000000000002862. Online ahead of print. PMID: 32496343 (IF 3,81)
- Framme C, Hoerauf H, **Wachtlin J**, Volkmann I, Bartram M, Junker B, Feltgen N. [Retinal Laser Treatment-Avoiding Mistakes](#). Ophthalmologe. 2020 Feb;117(2):169-188. doi: 10.1007/s00347-019-01035-y.
- Vogt D, **Wachtlin J**, Priglinger SG, Schumann RG. [Lamellar macular holes: Morphological characteristics and treatment success](#). Ophthalmologe. 2019 Nov;116(11):1020-1025. doi: 10.1007/s00347-019-00966-w.
- Haritoglou C, Wolf A, **Wachtlin J**. [Surgery of large and persistent macular holes](#). 2019 Nov;116(11):1011-1019. doi: 10.1007/s00347-019-00949-x.
- **Wachtlin J**, Schumann RG, Maier M, Haritoglou C. Macular changes in optic disc pits-Optic disc pit maculopathy (ODP-M) : Pathophysiology and possibilities of surgical treatment. Ophthalmologe. 2019 Nov;116(11):1026-1032. doi: 10.1007/s00347-019-0933-z. German. Erratum in: [Ophthalmologe. 2019 Oct 22::](#)
- Framme C, Eter N, Hamacher T, Hasanbasic Z, Jochmann C, Johnson KT, Kahl M, Sachs H, Schilling H, Thelen U, Wiedemann P, **Wachtlin J**. [Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany: Twelve-Month Outcomes of PERSEUS](#). Prospective Noninterventional Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients with Neovascular Age-Related Macular Degeneration Study Group. Ophthalmol Retina. 2018 Jun;2(6):539-549. doi: 10.1016/j.oret.2017.09.017. Epub 2017 Nov 20.
- Ziemssen F, **Wachtlin J**, Kuehlewein L, Gamulescu MA, Bertelmann T, Feucht N, Voegeler J, Koch M, Liakopoulos S, Schmitz-Valckenberg S, Spital G. [Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany](#); OCEAN study group. Diabetes Ther. 2018 Dec;9(6):2271-2289. doi: 10.1007/s13300-018-0513-2. Epub 2018 Oct 4.
- Paul C, Krug P, Müller HH, **Wachtlin J**, Mennel S, Müller S, Schmitz-Valckenberg S, Bertelmann T, Schumann RG. [Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth?](#) Graefes Arch Clin Exp Ophthalmol. 2018 Oct;256(10):1817-1822. doi: 10.1007/s00417-018-4055-0. Epub 2018 Jun 28. (IF: 1,991)

- Paul C, Heun C, Müller HH, Hoerauf H, Feltgen N, **Wachtlin J**, Kaymak H, Mennel S, Koss MJ, Fauser S, Maier MM, Schumann RG, Mueller S, Chang P, Schmitz-Valckenberg S, Kazerounian S, Szurman P, Lommatzsch A, Bertelmann T. [Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study](#). Br J Ophthalmol. 2018 Aug;102(8):1092-1097. doi: 10.1136/bjophthalmol-2017-310874. Epub 2017 Oct 31. (IF: 2,934)
- Schumann R, Wolf A, Hoerauf H, Lommatzsch A, Maier M, **Wachtlin J**, Koss MJ, Kreutzer T, Bertelmann T, Kazerounian T, Mennel S, Priglinger SG. Vitrectomy for persistent macular holes following ocriplasmin injection. Retina 2017 Dec;37(12):2295-2303. (IF: 3,039)
- Bertelmann T, **Wachtlin J**, Mennel S, Koss MJ, Maier MM, Schumann RG, Kazerounian S, Daniel H, Schmitz-Valckenberg S; EXPORT study group. [The predictability of ocriplasmin treatment effects: is there consensus among retinal experts? Results from the EXPORT study](#). Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1359-1367. (IF: 1,991)
- Eter N, Mohr A, **Wachtlin J**, Feltgen N. [Reply to a letter to the editor: Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial](#). Graefes Arch Clin Exp Ophthalmol. 2017 Feb;255(2):429-430. (IF: 1,991)
- Eter N, Mohr A, **Wachtlin J**, Feltgen N. German Ozurdex in RVO Real World Study Group Erratum to: Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical Graefes Arch Clin Exp Ophthalmol 2017 Jan;255(1):89. doi: 10.1007/s00417-016-3568-7. (IF: 1,991)
- **Wachtlin J**, Ringwald A, Maulhardt T, Pohl K, Wiedon A; BRIDGE investigators. [Cooperation of German ophthalmologists in routine care of patients with neovascular age-related macular degeneration: results of the non-interventional BRIDGE study](#). Graefes Arch Clin Exp Ophthalmol. 2016 Aug; 254(8):1529-36 (IF: 1,991)
- Eter N, Mohr A, **Wachtlin J**, Feltgen N. Reply to a letter to the editor: Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Response to a letter to the editor. Submitted Graefes Arch Clin Exp Ophthalmol 2016 Dec 12, [Epub ahead of print] (IF: 1,991)
- Gamulescu MA, Helbig H, **Wachtlin J**. [Differential diagnosis and therapy of pigment epithelial detachment](#). 2014 Jan; 111(1):79-90 (IF: 0.635)
- Schmitz K, Maier M, Clemens CR, Höhn F, **Wachtlin J**, Lehmann F, Bertelmann T, Rüdiger K, Horn M, Bezatis A, Spital G, Meyer CH; German Retinal Vein Occlusion Group. Reliability and safety of intravitreal Ozurdex injections. The ZERO study. 2014 Jan;111(1):44-52. (IF: 0,791)
- Bezatis A, Spital G, Höhn F, Maier M, Clemens CR, **Wachtlin J**, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up — the SOLO study. Acta Ophthalmol. 2013 Aug;91(5):e340-7 (IF: 2,512)
- **Wachtlin J**, Gamulescu MA. Age-Related macular degeneration. Part 2: Therapeutic procedures. Klin Monbl Augenheilkd. 2012 Oct;229(10):1049-59 (IF: 689)
- **Wachtlin J**, Gamulescu MA. Age-Related macular degeneration. Klin Monbl Augenheilkd. 2012 Sep;229(9):941-55 (IF:699)
- Huber M, **Wachtlin J**. Vitreous levels of proteins implicated in angiogenesis are modulated in patients with retinal or choroidal neovascularization. 2012;228(3):188-93. (IF: 1,412)
- Michels, M. Becker, **J. Wachtlin**, S. Binder. The intravitreal injection: Variations in regulations, cost and reimbursement in Europe. Spektrum Augenheilkunde 2012. (26) 401- 405 (IF 0,177)
- Heimann H, Yang Y, **Wachtlin J**, Pauleikhoff D. Differences in the treatment of exudative age-related macular degeneration in Germany and Great Britain. 2011 Jun;108(6):575-84. (IF: 0,617)
- Bechrakis NE, Petousis V, Willerding G, Krause L, **Wachtlin J**, Stroux A, Foerster MH. Ten-year results of transscleral resection of large uveal melanomas: local tumor control and metastatic rate. Br J Ophthalmol. 2010 Apr;94(4):460-6. doi: 10.1136/bjo.2009.162487. (IF: 2,934)
- **Wachtlin J**, Spyridaki M, Stroux A, Bechrakis NE, Foerster M. Therapy for peripapillary located and large choroidal haemangioma with PDT 'paint-brush technique'. Klin Monbl Augenheilkd. 2009 Nov;226(11):933-8. doi: 10.1055/s-0028-1109635. (IF: 0,542)

- Munkwitz S, Richter MN, Bechrakis NE, Foerster MH, **Wachtlin J**. Conservative and surgical treatment of bilateral keratomalacia in a patient with liver cirrosis and esophagitis. *Klin Monbl Augenheilkd*. 2009 Mar;226(3):191-2. (IF: 0,542)
- Gamulescu MA, Schubert K, Thormann S, Attaran M, Dueck N, Wiechens B, Spital G, Stroux A, **Wachtlin J**. ITAP-6-month results of a prospective, randomised phase 3 study for evaluation of the combination therapy of PDT and intravitreal trimacrolone in exudative AMD. *Klin Monbl Augenheilkd*. 2009 Jan;226(1):60-5. (IF: 0,542)
- Bechrakis NE, Petousis V, Krause L, **Wachtlin J**, Willerding G, Foerster MH. Surgical treatment modalities in uveal melanomas. *Klin Monbl Augenheilkd*. 2009 Nov;226(11):921-6. (IF: 0,542)
- Lang GE, Mennel S, Spital G, **Wachtlin J**, Jurklies B, Heimann H, Damato B, Meyer CH. Different indications of photodynamic therapy in ophthalmology. *Klin Monbl Augenheilkd*. 2009 Sep;226(9):725-39. (IF: 0,542)
- Krause L, Ritter C, **Wachtlin J**, Kreusel KM, Höcht S, Foerster MH, Bechrakis NE. Recurrence rate following adjuvant strontium-90 brachytherapy after excision of conjunctival melanoma. *Klin Monbl Augenheilkd*. 2008 Jul;225(7):649-52. (IF: 0,47)
- Ritter C, Renner AB, **Wachtlin J**, Bechrakis NE, Krause L. Tamoxifen retinopathy: a case series of clinical and functional data. 2008 Jun;105(6):544-9. (IF: 1,133)
- Ottenberg, J **Wachtlin**, M. H. Foerster, H Heimann. Subretinal fibrosis mimicking chorioretinal anastomosis following photodynamic therapy. *Retina Cases Brief Rep*. 2007 Spring;1(2):74-6. doi: 10.1097/01.ICB.0000264805.56364
- Höcht S, **Wachtlin J**, Bechrakis NE, Schäfer C, Heufelder J, Cordini D, Kluge H, Foerster M, Hinkelbein W. Proton or photon irradiation for hemangiomas of the choroid? A retrospective comparison. *Int J Radiat Oncol Biol Phys*. 2006 Oct 1;66(2):345-51. (IF 4,495)
- Kreusel KM, Bechrakis N, Riese J, Krause L, **Wachtlin J**, Foerster MH. Combined brachytherapy and transpupillary thermotherapy for large choroidal melanoma: tumor regression and early complications. *Graefes Arch Clin Exp Ophthalmol*. 2006 Dec;244(12):1575-80. (IF 1,991)
- Richter MN, **Wachtlin J**, Bechrakis NE, Hoffmann F. Keratoplasty after mustard gas injury: clinical outcome and histology. 2006 May;25(4):467-9. (IF 1.853)
- Michels, J. **Wachtlin**, M.A. Gamulescu, H. Heimann, C. Prünte, W. Inhoffen, I. Krebs, U. Schmidt-Erfurth. Comparison of Early Retreatment with the Standard Regimen in Verteporfin Therapy Of Neovascular Age-Related Macular Degeneration. *Ophthalmology* 2005, 112(12):2070-5 (IF 6.75)
- Voelker M, Gelissen F, Ziemssen F, **Wachtlin J**, Grisanti S. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2005;243(12):1241-1246 (IF 1,991)
- Heimann H, Gelissen F, **Wachtlin J**, Wehner A, Volker M. Foerster MH, Bartz Schmidt KU. Photodynamic therapy with verteporfin for choroidal neovascularisation associated with angioid streaks. *Graefes Arch Clin Exp Ophthalmol* 2005;243(11):1115-1123 (IF 1,991)
- Gabel-Pfisterer, A. Wehner, H. Heimann, M.H. Foerster, **Wachtlin**. Photodynamische Therapie mit Verteporfin bei Rezidiven choroidaler Neovaskularisationen (CNV) nach primärer Argonlaserkoagulation. *Der Ophthalmologe* 2005;102(6):592-6 (IF 0,635)
- **Wachtlin**, A. Stroux, A. Wehner, H. Heimann, M.H. Foerster. Photodynamic Therapy (PDT) with Verteporfin for choroidal neovascularisations (CNV) in clinical routine outside the TAP Study. – One and two-year results including juxtafoveal and extrafoveal CNV -. *Graefes Arch Clin Exp Ophthalmol* 2005;243(5):438-45. (IF 1,991)
- **Wachtlin**, N.E. Bechrakis, M.H. Foerster. Photodynamische Therapie mit Verteporfin beim Aderhautmelanom. Eine klinisch- histopathologische Pilotstudy. *Der Ophthalmologe* 2005;102(3):241-6 (IF 0,635)
- **Wachtlin**, A. Wehner, H. Heimann, M. H. Foerster. Photodynamische Therapie mit Verteporfin bei Patienten mit idiopathischer choroidaler Neovaskularisation. 2-Jahres-Ergebnisse. *Der Ophthalmologe* 2004, 101 (5): 489-495. (IF 0,635)
- Khairuddin, J. **Wachtlin**, W. Hopfenmüller, F. Hoffmann. HLA-A, HLA-B and HLA-DR matching reduces the rate of corneal allograft rejection. *Graefes Arch Clin Exp Ophthalmol* 2003, 241:1020-1028. (IF 1,991)

- **J. Wachtlin**, T. Behme, H. Heimann, U. Kellner, M.H. Foerster. Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefe's Arch Clin Exp Ophthalmol 2003, 241: 518-521. (IF 1,991)
- **Wachtlin**, H. Heimann, T. Behme, M.H. Foerster. Long-term results after Photodynamic Therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefe's Arch Clin Exp Ophthalmol 2003 241: 899-906. (IF 1,991)
- **Wachtlin**, S. Potthöfer, C. Jandack, U. Kellner, M.H. Foerster. Long-term results following pars plana vitrectomy with platelet concentrate in pediatric patients with traumatic macular hole. Am J Ophthalmol 2003, 136(1): 197-199. (IF 3,102)
- **Wachtlin**, R. Khairuddin, F. Hoffmann. Gewebetypisierung bei der perforierenden Keratoplastik. Der Ophthalmologe 2003, 100: 1021-1030. (IF 0,635)
- **J. Wachtlin**, H. Heimann, C. Jandack, K.M. Kreusel, N.E. Bechrakis, U. Kellner, M.H. Foerster. Bilateral vasoproliferative retinal tumors with identical localization in a pair of monozygotic twins. Arch Ophthalmol 2002, 120(6): 860-2. (IF 3,242)
- **Wachtlin**, NE Bechrakis, AO Schueler, H. Helbig, N. Bornfeld, MH. Foerster. Phacoemulsification following treatment of choroidal melanoma. Graefe's Arch Clin Exp Ophthalmol 2000, 238: 942-48. (IF 1,991)
- **Wachtlin**, K. Langenbeck, S. Schröder, E.P. Zhang, F. Hoffmann. Immunohistological and enzymhistological examinations of the corneal wound healing after Photorefractive Keratektomie (PRK) and Laser in situ Keratomileusis (LASIK). J Refract Surgery 1999, 15: 451-458. (IF 1,914)
- **Wachtlin**, I. E. Blasig, S. Schröder, K. Langenbeck, F. Hoffmann. PRK and LASIK, their potential risk of cataractogenesis: Lipid peroxidation changes in the aqueous humor and crystalline lens of rabbits. Cornea 1999, 19 (1): 75-79. (IF 1,833)
- P. Zhang, T. Pohl, S. Bulfone-Paus, **J. Wachtlin**, U. Kunzendorf, F. Hoffmann. Prolongation of corneal allograft survival by an interleukin-2-immunoglobulin fusion protein in mice. Graefe's Arch Clin Exp Ophthalmol 1998, 236: 486-492. (IF 1,991)
- Bulfone-Paus, H. von Bernuth, **J. Wachtlin**, D. Ungureanu, M. Notter, R. Rückert, H. Krause, T. Pohl, R. Paus, U. Kunzendorf. Local expression of interleukin-2-IgG fusion protein by engineered hematopoietic and epithelial tumor cells induces tumor rejection and immunity in mice. Cancer Research 1998, 58: 2707-10. (IF 7,514)
- **Wachtlin**, S. Schröder, D.T. Pham, F. Hoffmann, Chr. Hartmann. Intraokularer Tensionsanstieg bei Mikrokeratomschnitten (LASIK) und bei der Keratoplastik mit dem GTS Trepan. Der Ophthalmologe 1998, 95: 137-141. (IF 0,635)
- Hoffmann, E.P. Zhang, T. Pohl, U. Kunzendorf, **J. Wachtlin**, S. Bulfone Paus. Inhibition of corneal allograft reaction by CTLA4-Ig. Graefe's Arch Clin Exp Ophthalmol 1997, 235: 535-540. (IF 1,991)
- **Wachtlin**, A. Schüler, F. Hoffmann. Accuracy of corneal lenticules produced for lamellar refractive corneal surgery. Cornea 1995, 14 (3): 235-242. (IF 1,853)
- Hoffmann, A. Schüler, **J. Wachtlin**. Comparison of corneal lenticules produced for keratokypnosis and keratophakia. Ger J Ophthalmol 1993, 2: 395-399.
- Schüler, **J. Wachtlin**, R. Wolff, F. Hoffmann. Laser Stromal Keratomileusis using the Berlin Mikrokeratom. Eur J Implant Ref Surg 1993, 5 (6): 187-189.